Kit as a human oncogenic tyrosine kinase.
Signals through Kit receptor tyrosine kinase are essential for development of erythrocytes, melanocytes, germ cells, mast cells and interstitial cells of Cajal (ICCs). Mice and rats with a double gene dose of loss-of-function mutations of Kit show depletion of these cells. Although human homozygotes with loss-of-function mutations of Kit have not been reported, gain-of-function mutations of Kit result in development of tumors from mast cells, germ cells and ICCs in humans. The ICC tumors are called gastrointestinal stromal tumors (GISTs), and GISTs are a good target for the Kit inhibitor imatinib mesylate. The interrelationship between the type of Kit gain-of-function mutations and the therapeutic effect of imatinib mesylate has been well characterized in GISTs. Kit is interesting from both a biological and clinical view-point.
Kitamura
Y
Y
Shionogi Pharmaceutical Company, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan. yukihiko.kitamura@shionogi.co.jp
Hirotab
S
S
D000818:Animals; D001549:Benzamides; D019281:Dimerization; D046152:Gastrointestinal Stromal Tumors / Q000235:genetics / Q000378:metabolism; D006720:Homozygote; D006801:Humans; D000068877:Imatinib Mesylate; D007946:Leukemia, Mast-Cell / Q000378:metabolism; D051379:Mice; D008954:Models, Biological; D009154:Mutation; D009369:Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000378:metabolism; D009373:Neoplasms, Germ Cell and Embryonal / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics / Q000502:physiology*; D011743:Pyrimidines / Q000494:pharmacology; D051381:Rats; D015398:Signal Transduction; D013329:Structure-Activity Relationship
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit